15,163 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by Scientech Research LLC

Scientech Research LLC acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,163 shares of the biotechnology company's stock, valued at approximately $968,000.

Other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors lifted its holdings in Sarepta Therapeutics by 15.4% during the fourth quarter. Captrust Financial Advisors now owns 4,468 shares of the biotechnology company's stock worth $543,000 after acquiring an additional 597 shares in the last quarter. Cetera Investment Advisers lifted its holdings in Sarepta Therapeutics by 4.3% during the fourth quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock worth $1,359,000 after acquiring an additional 463 shares in the last quarter. EP Wealth Advisors LLC lifted its holdings in Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after acquiring an additional 105 shares in the last quarter. Focus Partners Wealth lifted its holdings in Sarepta Therapeutics by 30.0% during the fourth quarter. Focus Partners Wealth now owns 2,275 shares of the biotechnology company's stock worth $277,000 after acquiring an additional 525 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC bought a new position in Sarepta Therapeutics during the fourth quarter worth about $244,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SRPT has been the topic of several recent analyst reports. William Blair reiterated an "outperform" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Baird R W lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. BMO Capital Markets lifted their target price on Sarepta Therapeutics from $25.00 to $50.00 and gave the stock a "market perform" rating in a report on Tuesday, July 29th. Citigroup initiated coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They set a "sell" rating on the stock. Finally, Wells Fargo & Company boosted their price target on Sarepta Therapeutics from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $43.50.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $18.71 on Monday. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -21.51 and a beta of 0.49. The stock's 50-day moving average is $17.78 and its 200-day moving average is $43.48. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $138.81. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. Sarepta Therapeutics's revenue was up 68.4% on a year-over-year basis. Equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.